GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts

Our broader GLP-1 side effects investigation covers the headline adverse-event rates from the STEP and SURMOUNT trials. This article answers a different but higher- traffic question: how long do the side effects actually last? Three specific concerns drive the bulk of patient search volume — fatigue, hair loss, and the duration of the standard GI side effects — and the trial data is much more specific than most patients realize. We walk through each one with the verified numbers from the STEP-1 and SURMOUNT-1 prescribing information tables [1, 2, 3, 4] and the published clinical practice guidance on side-effect management [5, 6].

How long do the GI side effects last?

The classic GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, abdominal pain. The STEP-1 and SURMOUNT-1 trial publications don't report duration directly in the headline tables, but the timing pattern is consistent across both trials and across subsequent clinical practice reviews [5]:

• Onset: within hours to 2-3 days of the first injection, and within hours of each subsequent dose escalation.
• Peak intensity: first 1-2 weeks after any dose increase. The starter dose (0.25 mg semaglutide, 2.5 mg tirzepatide) is tolerated by most patients; the first two escalations (to 0.5 mg and 1.0 mg semaglutide; to 5 mg and 7.5 mg tirzepatide) tend to produce the strongest GI symptoms.
• Resolution: most patients report that nausea from any given dose step subsides within 1-2 weeks of continued dosing at that level. By the time the next escalation is due (end of week 4), most patients are back to baseline GI tolerance and the cycle repeats.
• Late course: by the time the maintenance dose is reached (week 16-20 on the standard ramp), roughly 50-60% of patients report no ongoing GI symptoms [5]. The remaining 40-50% have mild residual effects that persist at a stable level.

The Wharton 2022 clinical practice review on GI side effect management [5] documents that the standard trial-reported rates in STEP-1 (for nausea, ~44% at some point during the trial) substantially overstate the fraction of patients who have ongoing nausea at any given week — most nausea is peri-titration and transient.

Does semaglutide (or tirzepatide) make you tired?

“Does semaglutide make you tired?” is one of the highest-volume GLP-1 side-effect searches (~3,900/mo per Ahrefs). The direct answer from the FDA prescribing information tables is: yes, fatigue is a reported adverse event, but at a meaningfully lower rate than the GI symptoms.

Specific reported rates from the STEP-1 and Wegovy label adverse reactions table [1, 3]:

• Fatigue: reported in ~11% of STEP-1 semaglutide-treated patients vs ~5% of placebo, across the 68-week trial

From the SURMOUNT-1 and Zepbound label [2, 4]:

• Fatigue: ~7-8% in SURMOUNT-1 tirzepatide arms vs ~4% in placebo

Fatigue is real, documented, and modestly more common on GLP-1 therapy than on placebo. But the attribution is complicated: rapid weight loss by any mechanism is associated with fatigue, and GLP-1 patients by definition lose weight rapidly. It's difficult to separate drug-specific fatigue from the fatigue of a reduced-calorie week with 10-15% more weight loss than placebo.

Why fatigue happens on GLP-1s

1. Caloric deficit. The whole point of the drug is to reduce caloric intake, and the body responds to a 500-1000 kcal/day deficit with predictable fatigue during the first few weeks of any such deficit, regardless of the mechanism producing it.
2. Reduced protein intake. When appetite drops, protein intake usually drops disproportionately because high-protein foods (eggs, meat, Greek yogurt) are more filling and patients can't eat as much of them. Low protein intake worsens fatigue and also accelerates lean mass loss — see our semaglutide and muscle mass deep-dive for the protein targets.
3. Dehydration. GLP-1 patients commonly under-drink water because thirst and appetite signals are both blunted. Mild chronic dehydration is a major fatigue contributor and a fixable one.
4. Transient nausea-induced reduced sleep. Nausea that wakes a patient at night (especially in the first 1-2 weeks of each dose step) produces sleep fragmentation and next-day fatigue.
5. Vitamin deficiency. Reduced overall intake over months can produce B-vitamin, iron, and vitamin D deficiencies that all manifest as fatigue. Labwork is the quickest way to screen.

When fatigue should prompt medical attention

• Fatigue accompanied by dizziness, fainting, or persistent lightheadedness — possible dehydration or blood pressure drop.
• Fatigue accompanied by dark urine, reduced urine output, or abdominal pain — rule out dehydration-induced kidney injury (a documented GLP-1 concern, see Wegovy label warnings).
• Fatigue that doesn't improve after 4-6 weeks of dose stability and corrected protein + hydration.
• Fatigue with new shortness of breath — rule out cardiac or anemia causes unrelated to the GLP-1.

Does semaglutide or tirzepatide cause hair loss?

The Ahrefs data shows “does tirzepatide cause hair loss” at 4,200/mo with KD 0 — among the highest- volume, lowest-competition queries in the entire GLP-1 search universe. The answer from the trial data is specific and worth understanding.

Hair loss rates reported in the FDA prescribing information adverse reactions tables [3, 4]:

• Wegovy (STEP-1): alopecia reported in ~3% of semaglutide-treated patients vs ~1% of placebo.
• Zepbound (SURMOUNT-1): alopecia reported in ~5% of tirzepatide-treated patients vs ~1% of placebo.

Tirzepatide has a numerically higher rate than semaglutide, possibly reflecting the larger average weight loss in SURMOUNT-1 (~21%) vs STEP-1 (~15%). The important context: these rates are almost certainly driven by the weight loss itself rather than any drug-specific mechanism.

Telogen effluvium — the mechanism

The hair loss pattern that patients report on GLP-1s is classic telogen effluvium — a reversible shedding phase triggered by physiological stress, of which rapid weight loss is one of the most consistently documented causes [6]. The pattern:

1. Onset at 2-4 months after starting rapid weight loss. The hair follicles take 2-4 months to transition from growth phase to shedding phase after a triggering stress, so patients typically don't notice hair loss until they're already several months into GLP-1 therapy.
2. Diffuse thinning, not patchy. Telogen effluvium produces widespread thinning across the whole scalp, not bald patches. If you have bald patches, see a dermatologist — it's a different condition.
3. Shed lasts 3-6 months, then resolves. Once the triggering stress (rapid weight loss) stabilizes, the hair follicles cycle back into growth phase and the shed resolves. Most patients return to baseline hair density within 6-12 months of weight stabilization [6].
4. No permanent damage. Telogen effluvium is reversible. It does not cause permanent hair loss and it does not require stopping the medication to resolve.

What to do if you're losing hair on a GLP-1

• Confirm protein intake is adequate (1.2-1.6 g/kg of lean body mass per day). Low protein intake is the most-studied reversible contributor to diet-associated telogen effluvium.
• Check iron and ferritin. Iron deficiency without anemia is a common hair-loss amplifier in women on rapid-weight-loss diets. A simple CBC + ferritin blood test screens for it.
• Check vitamin D and B12. Both are associated with telogen effluvium when deficient.
• Wait. If labs are normal and protein is adequate, the condition is self-limited and resolves within 6-12 months of weight stabilization [6]. You do not need to stop the GLP-1 to recover.
• See a dermatologist if the shedding is patchy, if it lasts longer than 9 months without improvement, or if you notice scalp irritation. Minoxidil is not typically needed for telogen effluvium but can accelerate regrowth in motivated patients.

Duration reference table

Combining the STEP-1, SURMOUNT-1, Wegovy label, and Zepbound label data, here's a single-page reference for how long each major GLP-1 side effect typically lasts:

Red-flag symptoms that require medical attention

Most GLP-1 side effects are self-limiting and managed by dose-level adjustment, slower titration, and protein/hydration support. The following symptoms are different — they indicate potentially serious complications documented in the Wegovy and Zepbound labels [3, 4] and should prompt a call to your prescriber or ER visit:

• Severe abdominal pain radiating to the back (possible pancreatitis — stop the drug, go to ER)
• Yellowing of skin or eyes (gallbladder disease — evaluate urgently)
• Severe or persistent vomiting with dark urine or reduced urine output (dehydration, potential kidney injury)
• Signs of severe allergic reaction (swelling of face/throat, difficulty breathing, severe rash) — stop and go to ER immediately
• Visual changes in patients with type 2 diabetes (possible diabetic retinopathy progression)
• Neck lump, hoarseness, or difficulty swallowing — evaluate urgently (rare thyroid C-cell concern, label warning)

Related research and tools

For the broader side effect rate data, see our GLP-1 side effects investigation. For the onset and time-to-work curves that determine when each side effect peaks, see our how long does GLP-1 take to work guide. For the lean-mass preservation protein targets, see our semaglutide and muscle mass deep-dive. For injection site reactions and rotation technique, see our where to inject guide. For the dose plotter that visualizes how titration timing interacts with side-effect cycles, see our dose plotter.